Royalty Pharma PLC $RPRX Holdings Raised by Amundi

Amundi boosted its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 126.1% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,797,471 shares of the biopharmaceutical company’s stock after buying an additional 1,560,093 shares during the period. Amundi owned 0.50% of Royalty Pharma worth $101,240,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. USA Financial Formulas acquired a new stake in shares of Royalty Pharma in the 2nd quarter worth approximately $32,000. Summit Securities Group LLC acquired a new position in shares of Royalty Pharma during the first quarter valued at approximately $36,000. WPG Advisers LLC bought a new stake in Royalty Pharma during the first quarter worth approximately $39,000. MassMutual Private Wealth & Trust FSB raised its holdings in Royalty Pharma by 42.1% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,358 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 402 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its position in Royalty Pharma by 113.8% in the second quarter. Farther Finance Advisors LLC now owns 1,428 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 760 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

Shares of Royalty Pharma stock opened at $39.73 on Monday. Royalty Pharma PLC has a 12 month low of $24.05 and a 12 month high of $41.24. The company has a quick ratio of 3.48, a current ratio of 3.48 and a debt-to-equity ratio of 0.89. The stock has a market cap of $22.93 billion, a PE ratio of 30.10, a price-to-earnings-growth ratio of 2.09 and a beta of 0.46. The business has a fifty day simple moving average of $37.86 and a 200-day simple moving average of $36.39.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.06. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%.The firm had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. On average, sell-side analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, November 14th. Royalty Pharma’s dividend payout ratio is 66.67%.

Insider Buying and Selling

In other Royalty Pharma news, CFO Terrance P. Coyne sold 69,582 shares of Royalty Pharma stock in a transaction on Monday, December 1st. The shares were sold at an average price of $39.87, for a total transaction of $2,774,234.34. Following the completion of the sale, the chief financial officer owned 47,260 shares of the company’s stock, valued at $1,884,256.20. This trade represents a 59.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Marshall Urist sold 23,333 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $39.93, for a total transaction of $931,686.69. Following the transaction, the executive vice president owned 183,334 shares in the company, valued at approximately $7,320,526.62. This represents a 11.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 565,353 shares of company stock worth $22,153,184. 18.90% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the company. TD Cowen downgraded Royalty Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 17th. The Goldman Sachs Group initiated coverage on shares of Royalty Pharma in a research report on Tuesday, September 30th. They issued a “buy” rating and a $42.00 price target on the stock. Wall Street Zen lowered shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 28th. Morgan Stanley lowered their price objective on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Finally, Weiss Ratings lowered shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. Three investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $46.00.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.